C3 and paroxysmal nocturnal hemoglobinuria: Agents targeting various components, such as C5 inhibitors (e.g., eculizumab, ravulizumab), proximal C3 inhibitors (e.g., pegcetacoplan), and Factor B inhibitors, have received FDA approval for the treatment of PNH, with further indications under investigation (Zhang et al., 2024; Hillmen et al., 2006; Lee et al., 2019).